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Abstract
Background: Aging is known to induce immunosenescence, resulting in alterations in both the innate and adaptive
immune system. Here we evaluated the effects of aging on B cell subsets in peripheral blood of 155 immunologically
healthy individuals in four age categories (range 20-95y) via multi-parameter flow cytometry. Furthermore, we studied
the naive and antigen-experienced B cell receptor (BCR) repertoire of different age groups and compared it to the
clonal BCR repertoire of chronic lymphocytic leukemia (CLL), a disease typically presenting in elderly individuals.
Results: Total numbers and relative frequencies of B cells were found to decline upon aging, with reductions in
transitional B cells, memory cell types, and plasma blasts in the 70 + y group. The BCR repertoire of naive mature B cells
and antigen-experienced B cells did not clearly alter until age 70y. Clear changes in IGHV gene usage were observed in
naive mature B cells of 70 + y individuals, with a transitional pattern in the 50-70y group. IGHV gene usage of naive
mature B cells of the 50-70y, but not the 70 + y, age group resembled that of both younger (50-70y) and older (70 + y)
CLL patients. Additionally, CLL-associated stereotypic BCR were found as part of the healthy control BCR repertoire,
with an age-associated increase in frequency of several stereotypic BCR (particularly subsets #2 and #5).
Conclusion: Composition of the peripheral B cell compartment changes with ageing, with clear reductions in non-
switched and CD27 + IgG+ switched memory B cells and plasma blasts in especially the 70 + y group. The BCR
repertoire is relatively stable until 70y, whereafter differences in IGHV gene usage are seen. Upon ageing, an increasing
trend in the occurrence of particular CLL-associated stereotypic BCR is observed.
Keywords: Aging, B-lymphocyte, BCR repertoire, CLL, Stereotypic BCR
Background
Changes in the immune system related to aging generally
lead to increased susceptibility to infections, poor responses
to new and evolving pathogens, poor vaccination responses,
and higher incidence of autoimmune disorders and malig-
nancies [1, 2]. This decline in function of the immune
system, also referred to as immunosenescence, is the result
of alterations occurring in both innate and adaptive
immunity [3].
Age-related changes in humoral immune responses
have generally been ascribed to defects in the T cell
compartment and a lack of T cell help for B cell function
[3]. Nevertheless, mouse studies do provide evidence for
changes in the B cell compartment itself during aging.
Although total B cell numbers did not alter much, shifts
in the distribution of functional subsets were apparent
with old age. In fact, in old mice nearly 100% of splenic
B cells exhibited an antigen-experienced phenotype [4]
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and circulating immunoglobulins (Ig) were predomin-
antly derived from post-germinal center B cells, as de-
duced from the presence of somatic hyper mutations
(SHM) [5].
In human, age-related alterations in peripheral blood
(PB) B cell subset distribution have also been reported,
with circulating CD19+ B cells declining in absolute num-
bers and frequencies [6–10]. In some studies numbers and
percentages of CD27+ memory B cells were found to de-
cline [7, 8], whereas others showed an increase of these
cells [10–12]. Similarly, numbers and percentages of naive
CD27-IgD+ B cells were found to decrease by some stud-
ies [9, 10, 12], whereas others reported an increase [7, 8].
These inconsistent results may be explained by different B
cell subset definitions and/or by large inter-individual var-
iations in the studied age groups [11, 13].
Changes in B cell subsets during aging will likely also im-
pact on B cell receptor (BCR) repertoire diversity. Indeed,
in several mouse models age-related changes in the naive
BCR repertoire were reported [14]. In some elderly
humans, Ig heavy chain (IGH) complementarity determin-
ing region 3 (HCDR3) spectratyping analysis of PB B cells
revealed a significant loss of diversity, which was associated
with poor health status and poor survival [13]. Conflicting
data, however, were reported on SHM in IGHV genes of
the memory B cell compartment upon aging, varying from
increased mutation rates in IgG+ but not in IgM+ PB
memory B cells, to increased mutation rates in IgM+
memory B cells but not in other tonsillar subsets [15, 16].
Introduction of next generation sequencing (NGS)
technologies has opened new possibilities to analyze the
aging BCR repertoire, particularly in the light of immune
diseases that typically arise in elderly. One category of
immune diseases with a higher change to develop in
elderly humans are B cell malignancies, with chronic
lymphocytic leukemia (CLL) being the most common
type. Notably, in about one-third of CLL patients, quasi-
identical (stereotypic) BCRs are observed, which are
characterized by restricted IGHV, IGHD, and IGHJ gene
usage plus similarities in HCDR3 length and amino acid
sequence [17]. One study reported on stereotypic BCRs
within the normal IGHV1–69-IGHJ6 repertoire [18]. Lit-
tle is known however about the overall existence of
CLL-associated stereotypic BCRs in the normal BCR
repertoire of different age groups. We hypothesize that
these CLL-associated stereotypic BCR could be a reflec-
tion of changes in B cell subset distribution and the nor-
mal BCR repertoire upon aging.
In this study we determined absolute numbers and rela-
tive distribution of PB B cell subsets in healthy individuals
of different age categories. Additionally, we used NGS to
investigate the BCR repertoire of naive mature B cells and
different types of antigen-experienced B cells in healthy
individuals upon aging. Finally, we compared IGHV gene
usage of the normal BCR repertoire of different age
groups with that of CLL leukemic cells and evaluated the
occurrence of CLL-associated stereotypic BCR in the
aging normal BCR repertoire.
Results
Alterations in peripheral blood B cell subpopulations are
minor upon aging
To study B cell dynamics during aging, we performed
extensive flow cytometric immunophenotyping of per-
ipheral blood (PB) cells in a cohort of 155 immunologic-
ally healthy individuals of 20–95 years [< 50 (n = 47),
50–60 (n = 31), 60–70 (n = 45), and 70+ (n = 32)].
To validate our cohort, we first evaluated age-related
dynamics of the total white blood cells and lymphocyte
subpopulations (Fig. 1; Additional file 1: Figure 1). White
blood counts (WBC) remained stable across the age
groups (Fig. 1A). Although differences were not signifi-
cant, there was a trend that the absolute numbers of
lymphocytes was lower in the 50-60y and 60-70y groups
than in the <50y group (Additional file 1: Figure S1).
Both absolute and relative numbers of naive CD8+ T
cells significantly declined >50y of age, whereas absolute
and relative numbers of CD8+ effector (TemRA) T cells
clearly increased with increasing age and CD8+ effector
memory (TemRO) T cells remained stable (data not
shown). CD4+ T cell and NK cell numbers did not alter
between the age groups (Additional file 1: Figure S1).
These data are in line with previously reported data on
T and NK cells [19], thus supporting the validity of our
cohort for evaluating B cell aging effects.
Next, we focused on the composition of the B cell
compartment (see Methods, Additional file 6: Table S1,
Additional file 2: Figure S2) in the different age groups.
The total B cell numbers and relative frequencies of B cells
(as fraction of total lymphocytes) slightly declined during
aging, resulting in a significant difference between the <50y
and 70 + y groups (Fig. 1B-C). More specifically, we ob-
served a significant reduction in absolute numbers of tran-
sitional B cells in the 70 + y group, as well as reductions in
the non-switched and CD27 + IgG+ switched memory B
cell populations, and plasma blasts in the two oldest age
categories (Fig. 1D-M). For naive mature B cells and all
other types of memory B cells no clear alterations in abso-
lute numbers were noted upon aging (Fig. 1D-M). The
overall PB B cell subset distribution displayed only minor
shifts between different age groups (Fig. 1N), which was
mainly reflected by the significantly lower frequencies of
non-switched memory B cells and plasma blasts upon
increasing age (Additional file 3: Figure S3).
We then looked into CD5 + CD43+ chronically acti-
vated B cells, as these have been associated with CLL
and CLL-like MBL that typically appear in elderly [20–
22]. We noted a small but significant increase in relative
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frequencies of CD5 + CD43+ B cells in the 70 + y group
(when compared with the 60-70y age group), together
with a trend towards increased absolute numbers of
these cells (Fig. 2A-B). Next, we also evaluated CD21low B
cells, as high numbers of these cells have been associated
with autoimmune disease [23]. Notably, a significant in-
crease of CD21low cell numbers and relative frequencies
was seen between the 50-60y and 60-70y groups, which
normalized again in the 70 + y group (Figs. 2C-D).
Taken together, our B cell subpopulation analysis mostly
showed a decline in transitional B cells, non-switched and
CD27 + IgG+ switched memory B cells, and plasma blasts
in elderly. The frequency of CD21low B cells appeared to
be increased in 60-70y group.
Composition of the BCR repertoire of naïve mature B cells
is stable until 70y but shows changes in the 70 + y group
Our next aim was to see which differences occur in the
BCR repertoire of healthy donors during aging. To this
end, we first sorted antigen-inexperienced naive mature
B cells of healthy controls in the <50y, 50-70y, and 70 +
y groups (n = 4–5 per age group) and analyzed unique
IGHV-IGHD-IGHJ sequences and their HCDR3 regions
(Additional file 6: Table S2). Despite slight variations in
Fig. 1 B cells and B cell subpopulations in peripheral blood upon aging. a. WBC counts. b-c. Analysis of total cell numbers (b) and relative
frequencies (c) of B cells. d-n. Total numbers of different B cell subpopulations (d-m), and relative distribution of B cell subpopulations (n). Data
were evaluated for four age categories: < 50 (n = 47), 50–60 (n = 31), 60–70 (n = 45), and > 70 (n = 32). Statistical significance between age groups
was determined using the Mann-Whitney U test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001
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the mean HCDR3 lengths between the <50y (53.0 nucle-
otides), 50-70y (54.5 nucleotides), and 70 + y (46.1 nucle-
otides) groups, the overall HCDR3 profiles showed no
significant differences (Fig. 3A).
When evaluating gene usage, differences in IGHV
subgroup usage between the <50y and 50-70y groups
appeared limited, but we did find a marked increase
in IGHV1 and IGHV5 subgroup usage and a decrease
in IGHV4 subgroup usage in the 70 + y donors (Fig.
3B). Upon further examination of IGHV gene usage,
significant differences were mostly noted in the 70 + y
age group, with IGHV1–18, IGHV1–46, IGHV1–69,
and IGHV5–51 gene usage being significantly higher,
and IGHV4–34, IGHV4–39, and IGHV4–59 usage
being significantly lower (Fig. 3C), which could not
be explained by small clonal proliferations. That said,
the most commonly used IGHV gene in all three age
groups appeared to be the IGHV3–23 gene, followed
by IGHV3–21 (Fig. 3B). We did not detect clear dif-
ferences in IGHD and IGHJ gene usage between any
of the three age groups.
Collectively, our data from healthy controls of different
age groups suggest that the BCR repertoire of naive
mature B cells is relatively stable until 70y. In contrast,
in the 70 + y group IGHV gene usage does differ, which
most probably should be interpreted as an aging effect,
since there were no other indications that can explain
this difference.
Differences in BCR repertoire of memory B cell
subpopulations are minor between <50y and 50-70y age
groups
To evaluate age effects in the antigen-selected BCR rep-
ertoire, we then focused on non-switched, IgM-only, and
CD27 + IgG+ switched memory B cells, which are all
antigen-experienced cells though arising via distinct acti-
vation routes. Some of the memory B cell populations
are so small that they can only be sorted from buffy
coats of healthy donors (n = 4–5 per age group); unfor-
tunately blood donors are only allowed to give blood
until 70y, so we could not the study the 70 + y age
group. Mean HCDR3 lengths did not differ significantly
between the <50y and 50-70y age groups (Add-
itional file 4: Figure S4). IGHV, IGHD, and IGHJ gene
usage and combined IGHV / IGHJ patterns of non-
switched, IgM-only, and CD27 + IgG+ memory B cells
did not show significant differences either between these
two age groups (Additional file 5: Figure S5). Notably,
when analyzing SHM frequencies for these memory B
cell subpopulations, we did detect a higher mutation rate
for non-switched and IgM-only memory B cells in the
50-70y group, whilst a small reduction in mutation fre-
quency was seen in CD27 + IgG+ switched memory B
cells (Additional file 5: Figure S5).
Collectively these data show that the BCR characteris-
tics of memory B cell subpopulations do not differ statis-
tically between the <50y and 50-70y groups.
Fig. 2 CD43 + CD5+ B cells and CD21low B cells in peripheral blood upon aging. Analysis of total cell numbers (a,c) and relative frequencies (b,d) of
CD5 + CD43+ B cells and CD21low B cells, respectively. Data were evaluated for four age categories: < 50 (n = 47), 50–60 (n = 31), 60–70 (n = 45), and > 70
(n = 32). Statistical significance between age groups was determined using the Mann-Whitney U test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001
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Fig. 3 (See legend on next page.)
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IGHV gene usage in the clonal BCR repertoire of CLL
patients is largely comparable to IGHV genes in naive
mature B cells of 50-70y individuals
As the BCR is known to play an important role in dis-
ease onset and prognosis of CLL, which normally de-
velops at elderly age (average 70 + y), we then asked
whether overall IGHV gene usage in CLL patients of dif-
ferent age groups would reflect the BCR repertoire of
normal B cells of the same age groups. To this end we
evaluated IGHV gene usage in different B cell subsets of
healthy controls of different age groups and compared
the profiles with Sanger sequencing-based data of a
cohort of 920 CLL patients (Fig. 4).
Overall IGHV gene usage profiles did not differ sig-
nificantly between different types of normal B cell
subpopulations, such as naive mature B cells, non-
switched memory B cells, and IgM-only memory B
cells, in the 50-70y age group (p = 0.99–1 in all com-
parisons). Unfortunately, no such comparison was
possible in 70 + y individuals, due to the lack of avail-
able data from non-switched and IgM-only memory B
cells for this age group. However, overall IGHV gene
usage profiles in naive mature B cells of healthy indi-
viduals did clearly vary between the 50-70y and 70 + y
groups (p = 0.005).
When we next compared overall IGHV gene usage
profiles between CLL patients of the 50-70y and the
70 + y groups we did not observe a significant differ-
ence (p = 0.995). The IGHV profiles of naive mature
B cells and CLLs in the 50-70y group appeared to
look rather similar (p = 0.574), albeit with a more
dominant IGHV1–69 and IGHV4–34 usage in CLL.
In contrast, naive mature B cell and CLL IGHV gene
usage profiles in the 70 + y groups were clearly differ-
ent (p < 0.0001), while the overall IGHV profile in
70 + y CLL was in fact rather similar to that of naive
mature B cells of the 50-70y age group (p = 0.110).
Furthermore, overall IGHV profiles in the 50-70y
group appeared clearly different between CLL and
non-switched memory B cells (p = 0.028) or IgM-only
memory B cells (p = 0.004).
These data indicate that the overall IGHV gene usage
profile in CLL patients, irrespective of the age of presen-
tation, is similar to naive mature B cells of especially the
50-70y control group. The overall IGHV profile of the
70 + y control group is different without obvious explan-
ation as mentioned above.
CLL-associated stereotypic BCR are present in naive
mature B cells and increase with age
In view of the occurrence of quasi-identical (stereotypic)
BCR with similar IGHV / IGHD / IGHJ and HCDR3 fea-
tures in CLL clones of different patients, we then investi-
gated whether we could also detect stereotypic BCR in
healthy individuals of different age groups. To identify
CLL-related stereotypic BCRs in the normal repertoire of
healthy controls of different age groups, a reference data-
base of stereotypic BCR from CLL patients [24] was used
for assigning individual IGH sequences from healthy con-
trols. With this algorithm we could indeed identify CLL-
associated stereotypic BCRs based on HCDR3 characteris-
tics in the repertoire of naive mature B cells, and also of
non-switched, IgM-only, and CD27 + IgG+ switched
memory B cells (Fig. 5). The presence of stereotypic BCR
receptors in naive mature B cells showed an increasing
trend with age and was most apparent in the 70 + y group
(Fig. 5A). In naive mature B cells, the most prominent
stereotypic BCR belonged to CLL subsets #2, #5, and #64B
(Fig. 5B). In non-switched memory B cells the most fre-
quently found stereotypic BCRs concerned CLL subsets #2
and #14 (Fig. 5C). The CLL#14 BCR also appeared most
prominent in IgM-only and CD27 + IgG+ switched mem-
ory B cells, especially in the 50-70y category (Fig. 5D-E).
From these findings we conclude that CLL-associated
stereotypic BCRs are present in the normal BCR reper-
toire during life and that their frequency showed an
increasing trend upon aging.
Discussion
Here we evaluated age-related changes in B cell subset
composition as well as BCR repertoire with a focus on
CLL-associated stereotypic BCR usage. In the most eld-
erly (70 + y) individuals we observed a decline in abso-
lute numbers of transitional B cells, total memory B
cells, and plasma blasts. The BCR repertoire of naive
mature B cells and distinct memory B cell populations
was found to be relatively stable until 70y. In naive ma-
ture B cells of the 70 + y group differences were noted,
especially with respect to IGHV gene usage. Notably,
IGHV gene usage in the clonal BCR repertoire in CLL
did not differ with the age of presentation of the CLL
patients, and largely resembled naive mature B cells of
the 50-70y group rather than the 70 + y group. Finally,
CLL-associated stereotypic BCR were found as part of
(See figure on previous page.)
Fig. 3 BCR repertoire analysis in naive mature B cells upon aging. a. Comparison of HCDR3 lengths in < 50, 50–70, and 70 + y age categories.
Statistical significance was determined using the Kolmogorov-Smirnov test. b. Circos plots of the combination of IGHV-IGHJ gene usage in < 50,
50–70, and 70 + y age categories. c. Differences in IGHV gene usage frequencies upon aging. Statistical significance between different age groups
was determined using the two-way ANOVA test (with Bonferroni multiple comparisons correction); *, p < 0.05; **, p < 0.01; ***, p < 0.001;
****, p < 0.0001
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the BCR repertoire of healthy individuals and their fre-
quencies increased with age.
The observed decline in total B cell numbers in the 70 +
y group could result from a reduced output from the bone
marrow [25, 26]. An alternative explanation could be the
reduction in CD27+ antigen-experienced B cell subpopula-
tions. Non-switched and CD27 + IgG+ memory B cells to-
gether make up the majority of the CD27+ memory B cell
Fig. 4 Comparison of IGHV gene usage in the normal BCR repertoire of healthy individuals and the clonal CLL repertoire of different age groups.
a-b. IGHV gene usage in naive mature B cells of 50-70y (A) and 70 + y (b) healthy controls. c-d. IGHV gene usage in non-switched (c) and IgM-
only B (d) cells of 50-70y healthy controls. E-F. IGHV gene usage in clones of CLL patients of 50-70y (c) and 70 + y (d). Statistical analysis was
determined using the Fisher’s exact test; see text for details on significance levels
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compartment, and were previously described to decline
upon aging [6]. The decline in non-switched memory B
cells could underlie the higher vulnerability to diseases
caused by encapsulated bacteria like Streptococcus pneumo-
niae in elderly [27]. CD27 + IgG+ memory B cells are
mainly, albeit not exclusively, formed in T cell-dependent
immune responses and play a role in recall responses to
previously encountered pathogens [28]. The reduction of
plasma blasts upon aging is in line with earlier observations
[29] and fits the lower immunoglobulin levels in the circu-
lation as reported in elderly [30]. Together these data could,
at least partially, explain the reduced effects of vaccination
and immune responses against infections in elderly.
Chronically activated B cells express CD5 and CD43
[31, 32] and might trigger MBL onset. [33, 34]. MBL are
found in healthy adult individuals, with an incidence that
increases with age to roughly 10% of individuals >65y
[35]. Based on their phenotypical association with MBL
[20] and CLL [22], the increase of CD5 + CD43+ B cells
upon aging might thus correlate with the higher risk of
MBL and CLL clones in elderly. Another B cell subset
related with chronic activation concerns CD21low B cells,
increased numbers of which can be found in patients show-
ing chronic inflammation in the context of autoimmune
disease [23]. As we excluded individuals with inflammatory
and (auto)immune disease in our immunologically healthy
cohort, unfortunately we could not link the higher number
of CD21low B cells in the 60-70y group to overt auto-
immune disease occurrence. Nevertheless, increased num-
bers of CD21low B cells in this age group might reflect an
Fig. 5 Stereotypic BCR in the normal BCR repertoire of healthy aging individuals. a. Total frequency of stereotypic BCR in the normal BCR
repertoire in naive mature B cells of healthy individuals. b-e. Frequency of stereotypic BCR assigned to CLL-associated stereotypic subsets in naive
mature (b), non-switched (c), IgM-only (d), and CD27 + IgG+ switched (e) memory B cells. Statistical significance between different age groups
was determined using the two-way ANOVA test (with Bonferroni multiple comparisons correction); *, p < 0.05; **, p < 0.01; ***, p < 0.001;
****, p < 0.0001
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increased incidence of, yet undiagnosed, autoimmune
diseases upon aging.
BCR repertoire changes were most apparent in naive
mature B cells of the 70 + y group. Since naive mature B
cells are not affected by exogenous antigen, this is most
likely the result of changes in repertoire development and/
or output from the bone marrow. Whilst HCDR3 length,
IGHD, and IGHJ usage remained stable in all three age
categories, IGHV gene usage did reveal alterations. Inter-
estingly, IGHV4–34 usage, a gene often associated with
autoimmunity, was found to be reduced upon aging in
these healthy individuals. Upon aging we also noticed a
combined increased usage of IGHV5–51 and IGHV1–69,
in line with a previous report [36]. IGHV1–69 has been
associated with broadly neutralizing antibodies against
amongst others influenza, HIV, hepatitis C, and com-
mensal bacteria antigens in the context of CLL [37].
Remarkably, IGHV gene usage in both the 50-70y and
70 + y CLL patient groups most closely resembled IGHV
gene usage in naive mature B cells of 50-70y, but not 70 +
y, healthy individuals. One could speculate that CLL
clones, even the ones in elderly CLL patients (70 + y),
would have developed from B cells with a BCR repertoire
of relatively younger age (<70y), but it might also reflect
selection for IGHV specificities in the younger repertoire
that could be predisposing for CLL development.
Stereotypic BCR, which are found in roughly one third
of CLL clones, have previously been documented in
RNA from a total lymphocyte pool of three healthy indi-
viduals (age 50, 69, and 69) [38, 39]. In this study we
show that stereotypic BCR can be found in the normal
BCR repertoire of both naive mature and antigen-experi-
enced B cells. Interestingly, a frequently observed stereo-
typic BCR was the CLL#2 BCR (IGHV3–21 in
combination with IGHJ6 with a short HCDR3 length of
9 amino acids), which is the most common stereotypic
BCR seen in CLL patients and is associated with an ag-
gressive form of CLL [17, 40]. Stereotypic CLL#5 BCR
(IGHV1–69, IGHD3–10/3–3, IGHJ6, 20 amino acids
HCDR3) as well as stereotypic CLL#64 BCR (IGHV3
subgroup genes, IGHD2 subgroup genes, IGHJ6, 21
amino acids HCDR3) [17] were relatively often detected
in naive mature B cells of especially individuals 70 + y. In
antigen-experienced B cells, stereotypic CLL#14 BCR
(IGHV4–4, no specific IGHD, IGHJ4, and short 10
amino acids HCDR3) was frequently found. The possi-
bility to detect stereotypic BCRs with short HCDR3
lengths in antigen-experienced B cell subpopulations
would be in line with our observation that on average
the complete memory BCR repertoire shows selection
for shorter HCDR3 lengths in comparison with naive
B cells. Notably, other common CLL-associated
stereotypic BCR, such as CLL#4, CLL#6, and CLL#8
BCR, could not be detected.
Even though the frequency of stereotypic BCR in
healthy B cells shows a trend towards increase with age,
stereotypic BCR can already be detected in cord blood
(data not shown) and thus are to be considered as part of
the normal BCR repertoire. Moreover, even though the
increase of CLL-associated stereotypic BCR in the aging
normal BCR repertoire might imply an increased predis-
position for CLL development in elderly, it should be
stressed that two thirds of CLL show heterogeneous BCR
specificities that can also mediate derailment of B cells
leading to CLL. Investigations into the presence of CLL-
associated stereotypic BCR in healthy individuals should
therefore be extended to larger datasets including more
healthy individuals of all age groups, as well as to individ-
uals suffering from chronic infection, immunodeficiency,
or autoimmune disease. Such studies would allow to
define the true impact of CLL-associated stereotypic BCR
in CLL development.
Conclusion
We analyzed the peripheral B cell compartment and BCR
repertoire during human ageing. Composition of the per-
ipheral B cell compartment changes with ageing, with clear
reductions in non-switched and CD27 + IgG+ switched
memory B cells and plasma blasts in especially the 70 + y
group. The BCR repertoire is relatively stable until 70y
age, whereafter differences in IGHV gene usage are seen.
Upon ageing, an increase in the occurrence of particular
CLL-associated stereotypic BCR is observed, potentially
reflecting the occurrence of such BCR in CLL in elderly.
Methods
Sample inclusion
For B cell subpopulation analysis, peripheral blood (PB) of
immunologically healthy individuals was obtained from
pre-surgery patients (Dept. Orthopedics, Erasmus MC)
with the following exclusion criteria: (auto)immune or
inflammatory diseases; malignancies; usage of anti-inflam-
matory or immunosuppressive drugs; surgery in the past
30 days; alcohol and drug abuse. To increase the number
of subjects per age group, additional samples from the
SENEX healthy aging cohort (Rheumatology and Clinical
Immunology, UMCG, Groningen, Netherlands), and sam-
ples from co-workers from the department were included.
Subjects (n = 155) were divided into four age categories: <
50 (n = 47), 50–60 (n = 31), 60–70 (n = 45), and 70+ (n =
32). For the BCR repertoire study, peripheral blood samples
(n = 5 per age group) were additionally obtained from San-
quin Blood bank (Amsterdam, The Netherlands). Diagnos-
tic samples from CLL patients were collected upon
informed consent and anonymized for further usage. Writ-
ten consent was obtained in accordance with the Declar-
ation of Helsinki after medical ethics committee approval
(MEC 2011–409, 2016–202, and 2,012,375).
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Immunophenotyping of B cell subpopulations
Folllowing white blood cell count (WBC) measurement
on a Coulter®Ac.T diff analyzer (Beckman Coulter, Fuller-
ton, CA, USA), flowcytometry was performed on whole
blood [after red blood cell lysis with ammonium chloride]
using an LSR Fortessa™ (BD Biosciences, San Jose, CA).
Absolute cell counts of monocytes, natural killer (NK)
cells, T cells, and B cells were calculated from WBC num-
bers using Infinicyt software (Cytognos, Salamanca,
Spain). Lymphocytes were first gated based on FSC / SSC
characteristics, and B cells were defined by expression of
the pan-B cell marker CD19. Further gating was per-
formed for defined CD19+ B cell subpopulations, i.e. tran-
sitional B cells (CD38hi/CD27-), naive mature B cells
(CD38−/CD27−/IgM+/IgD+), non-switched memory B
cells (CD38−/CD27+/IgM+/IgD+), IgM-only B cells
(CD38−/CD27+/IgM+/IgD-), switched memory B cells
(CD38−/CD27+ or −/IgM−/IgD-IgG+ or IgA+ or IgE+),
plasma blasts (CD38hi/CD27+), CD5+/CD43+ B cells
(CD38−/CD5+/CD43+), and CD21low B cells (CD38dim/
CD21low) according to published data [28] (see also (Add-
itional file 6: Table S1), using 11-color flowcytometric
stainings (Additional file 6: Table S3) and FACS DIVA
software (BD Biosciences) for analysis.
Sorting of B cell subpopulations and DNA isolation
PB mononuclear cells (PB-MNC) were isolated via Ficoll
Paque gradient centrifugation. Subsequently, B cells were
purified with human CD19 MicroBeads via AutoMACS
(Myltenyi Biotech, Bergisch Gladbach, Germany). Next,
several B cell subpopulations (naive mature, non-switched
memory, IgM only, and CD27+/IgG+) were collected using
a FACSAria cell sorter (BD Biosciences). Immediately after
collection cells were lysed in RLT+ buffer (QIAGEN,
Valencia, CA) complemented with β-mercapto-ethanol.
Cells were used for DNA isolation with the DNA/RNA/
miRNA Easy kit (QIAGEN) and/or stored in − 80 °C for
later processing.
NGS-based BCR repertoire analysis of healthy individuals
IGHV-IGHD-IGHJ rearrangements were amplified from
100 ng DNA of sorted B cell subpopulations (from n = 3–5
healthy controls per age group; see Additional file 6: Table
S3) using the BIOMED-2 IGH multiplex PCR with 6 IGHV
primers and 1 IGHJ consensus primers that were extended
with adapter sequences for NGS. PCR products were puri-
fied by gel extraction (QIAGEN) and subsequently by
Agencourt AMpure XP beads (Beckman Coulter, Brea,
CA). Concentrations were measured using Quant-iT Pico-
green dsDNA assay (Invitrogen, Carlsbad, CA). PCR prod-
ucts were sequenced on a 454 GS junior (Roche, Branford,
CT), using the GS Junior Titanium emPCR, sequencing,
and PicoTiterPlate kits (Roche), and partly on a MiSeq
(Illumina, San Diego, CA) platform. Cross-validation
experiments using B cells from healthy individuals showed
comparability of data from both platforms (unpublished;
see Additional file 7). Sequences were demultiplexed based
on their multiplex identifier sequence and trimmed via the
ImmunoGlobulin galaxy (IGGalaxy) pipeline [41]. FASTA
files were uploaded in IMGT/High-V-QUEST (http://www.
imgt.org/HighV-QUEST/login.action) and IMGT output
files were further analyzed in the Antigen Receptor Galaxy
pipeline, as described before [42].
For comparison purposes, a local Erasmus MC cohort
of 920 CLL patients (mean 65y) was used, in which Sanger
sequencing-based IGHV mutation status analysis was per-
formed using the BIOMED-2 primers and protocol [43],
and following ERIC interpretation guidelines [44].
IGHV-IGHJ circos plots were generated via the Circos
Table Viewer (http://mkweb.bcgsc.ca/tableviewer/). CLL-
associated stereotypic BCR in healthy control samples were
defined using the ARResT/AssignSubsets tool (http://tools.
bat.infspire.org/arrest/assignsubsets/).
Statistical analysis
Significant differences in relative and absolute numbers
of lymphocyte subpopulations and IGH SHM levels be-
tween age groups were determined using the Mann-
Whitney U test. Differences in HCDR3 lengths were
evaluated using Kolmogorov-Smirnov statistics. Relative
IGHV gene usage and relative frequencies of stereotyped
BCR between different age groups were analyzed using a
two-way ANOVA with multiple comparisons. Overall
IGHV gene usage between B cell subpopulations and
CLL clones was analyzed using the Fisher’s exact test. A
p-value < 0.05 was considered significant. Statistics were
performed in GraphPad Prism v5.0 (La Jolla, CA).
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